艾滋病相关卡波西肉瘤的局部卤泛酮 II 期艾滋病恶性肿瘤联合会试验。
Phase II AIDS Malignancy Consortium trial of topical halofuginone in AIDS-related Kaposi sarcoma.
机构信息
Ireland Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
出版信息
J Acquir Immune Defic Syndr. 2011 Jan 1;56(1):64-8. doi: 10.1097/QAI.0b013e3181fc0141.
Abstract
Using a novel blinded intrapatient vehicle control design, we conducted a phase II study of topically administered halofuginone, an angiogenesis inhibitor that inhibits collagen type-I and matrix metalloproteinases (MMPs), in patients with AIDS-related Kaposi sarcoma. Serial Kaposi sarcoma biopsies assessed treatment effects on angiogenic factors and Kaposi sarcoma herpesvirus-latency associated nuclear antigen-1 (KSHV-LANA). We observed marked heterogeneity of KSHV-LANA expression. Although the small number of subjects whose response could be evaluated precluded definitive assessment of halofuginone's efficacy, we observed a significant decrease in type-I collagen only in halofuginone-treated lesions, but no effect on MMP-2. The trial design is applicable to future studies of topical agents.
摘要
采用新型盲法患者自身对照设计，我们开展了一项局部给予海夫定的 II 期研究，海夫定为血管生成抑制剂，可抑制 I 型胶原和基质金属蛋白酶（MMPs）。该研究入组了 AIDS 相关性卡波西肉瘤患者。对卡波西肉瘤活检标本进行连续检测，以评估血管生成因子和卡波西肉瘤疱疹病毒潜伏相关核抗原-1（KSHV-LANA）的治疗效果。我们观察到 KSHV-LANA 表达存在明显异质性。尽管可评估应答的受试者数量较少，无法明确评估海夫定的疗效，但我们仅观察到海夫定治疗病灶中 I 型胶原显著减少，但对 MMP-2 无影响。该试验设计适用于未来的局部药物研究。
相似文献
1
Phase II AIDS Malignancy Consortium trial of topical halofuginone in AIDS-related Kaposi sarcoma.艾滋病相关卡波西肉瘤的局部卤泛酮 II 期艾滋病恶性肿瘤联合会试验。
J Acquir Immune Defic Syndr. 2011 Jan 1;56(1):64-8. doi: 10.1097/QAI.0b013e3181fc0141.
2
Pilot Trial AMC-063: Safety and Efficacy of Bortezomib in AIDS-associated Kaposi Sarcoma.AMC-063 试验：硼替佐米治疗艾滋病相关卡波西肉瘤的安全性和疗效。
Clin Cancer Res. 2020 Feb 1;26(3):558-565. doi: 10.1158/1078-0432.CCR-19-1044. Epub 2019 Oct 17.
3
Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group.外用阿利维A酸（9-顺式维甲酸）凝胶治疗艾滋病相关皮肤卡波西肉瘤。泛维甲酸凝胶北美研究小组。
J Acquir Immune Defic Syndr. 1999 Nov 1;22(3):235-46. doi: 10.1097/00126334-199911010-00004.
4
Interferon-alpha2b with protease inhibitor-based antiretroviral therapy in patients with AIDS-associated Kaposi sarcoma: an AIDS malignancy consortium phase I trial.α-干扰素2b联合基于蛋白酶抑制剂的抗逆转录病毒疗法治疗艾滋病相关卡波西肉瘤患者：一项艾滋病恶性肿瘤联盟I期试验
J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):149-53. doi: 10.1097/01.qai.0000194237.15831.23.
5
Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042.艾滋病相关卡波西肉瘤伊马替尼的 II 期临床试验：艾滋病恶性肿瘤联盟方案 042。
J Clin Oncol. 2014 Feb 10;32(5):402-8. doi: 10.1200/JCO.2012.48.6365. Epub 2013 Dec 30.
6
Topical treatment of cutaneous lesions of acquired immunodeficiency syndrome-related Kaposi sarcoma using alitretinoin gel: results of phase 1 and 2 trials.使用阿利维A酸凝胶对获得性免疫缺陷综合征相关卡波西肉瘤的皮肤病变进行局部治疗：1期和2期试验结果
Arch Dermatol. 2000 Dec;136(12):1461-9. doi: 10.1001/archderm.136.12.1461.
7
New drug targets in Kaposi sarcoma.卡波西肉瘤的新药物靶点。
Expert Opin Ther Targets. 2010 Dec;14(12):1355-66. doi: 10.1517/14728222.2010.532336. Epub 2010 Nov 2.
8
Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium.
Cancer. 2008 Mar 1;112(5):1083-8. doi: 10.1002/cncr.23108.
9
Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team.血管生成抑制剂IM862在一项III期试验中对艾滋病相关卡波西肉瘤无效，但显示出高效抗逆转录病毒疗法的持续强效作用：来自艾滋病恶性肿瘤协会和IM862研究团队。
J Clin Oncol. 2005 Feb 10;23(5):990-8. doi: 10.1200/JCO.2005.11.043. Epub 2004 Dec 14.
10
Gel approved for KS.
AIDS Patient Care STDS. 1999 May;13(5):309. doi: 10.1089/apc.1999.13.309.
引用本文的文献
1
Targeting collagen to optimize cancer immunotherapy.靶向胶原蛋白以优化癌症免疫疗法。
Exp Hematol Oncol. 2025 Jul 29;14(1):101. doi: 10.1186/s40164-025-00691-y.
2
Traditional medicine meets modern science: Halofuginone's role in combating autoimmune diseases.传统医学与现代科学相遇：常山酮在对抗自身免疫性疾病中的作用。
J Nat Med. 2025 Jun 30. doi: 10.1007/s11418-025-01927-1.
3
Halofuginone for non-hospitalized adult patients with COVID-19 a multicenter, randomized placebo-controlled phase 2 trial. The HALOS trial.羟基脲治疗非住院成人 COVID-19 患者的多中心、随机、安慰剂对照 2 期试验。HALOS 试验。
PLoS One. 2024 Feb 23;19(2):e0299197. doi: 10.1371/journal.pone.0299197. eCollection 2024.
4
Control of fibrosis with enhanced safety via asymmetric inhibition of prolyl-tRNA synthetase 1.通过不对称抑制脯氨酰-tRNA 合成酶 1 来控制纤维化，提高安全性。
EMBO Mol Med. 2023 Jul 10;15(7):e16940. doi: 10.15252/emmm.202216940. Epub 2023 May 22.
5
Metabolic reprogramming in cancer: Mechanisms and therapeutics.癌症中的代谢重编程：机制与治疗方法。
MedComm (2020). 2023 Mar 27;4(2):e218. doi: 10.1002/mco2.218. eCollection 2023 Apr.
6
The KEAP1-NRF2 System and Esophageal Cancer.KEAP1-NRF2系统与食管癌
Cancers (Basel). 2022 Sep 27;14(19):4702. doi: 10.3390/cancers14194702.
7
Topical treatments for Kaposi sarcoma: A systematic review.卡波西肉瘤的局部治疗：一项系统评价。
Skin Health Dis. 2022 Apr 8;2(2):e107. doi: 10.1002/ski2.107. eCollection 2022 Jun.
8
Oncologic Treatment of HIV-Associated Kaposi Sarcoma 40 Years on.HIV 相关卡波西肉瘤的肿瘤治疗：40 年进展。
J Clin Oncol. 2022 Jan 20;40(3):294-306. doi: 10.1200/JCO.21.02040. Epub 2021 Dec 10.
9
Nanosecond pulsed electric fields induce the integrated stress response via reactive oxygen species-mediated heme-regulated inhibitor (HRI) activation.纳秒级电脉冲通过活性氧介导的血红素调节抑制剂 (HRI) 激活诱导整体应激反应。
PLoS One. 2020 Mar 10;15(3):e0229948. doi: 10.1371/journal.pone.0229948. eCollection 2020.
10
Cancer-Associated Fibroblasts Build and Secure the Tumor Microenvironment.癌症相关成纤维细胞构建并稳固肿瘤微环境。
Front Cell Dev Biol. 2019 Apr 24;7:60. doi: 10.3389/fcell.2019.00060. eCollection 2019.
本文引用的文献
1
Halofuginone inhibits TH17 cell differentiation by activating the amino acid starvation response.常山酮通过激活氨基酸饥饿反应来抑制辅助性T细胞17（TH17）细胞分化。
Science. 2009 Jun 5;324(5932):1334-8. doi: 10.1126/science.1172638.
2
Kaposi's sarcoma-associated herpesvirus infection promotes invasion of primary human umbilical vein endothelial cells by inducing matrix metalloproteinases.卡波西肉瘤相关疱疹病毒感染通过诱导基质金属蛋白酶促进人原代脐静脉内皮细胞的侵袭。
J Virol. 2007 Jul;81(13):7001-10. doi: 10.1128/JVI.00016-07. Epub 2007 Apr 18.
3
Gene expression during chemically induced liver fibrosis: effect of halofuginone on TGF-beta signaling.化学诱导肝纤维化过程中的基因表达：卤夫酮对转化生长因子-β信号传导的影响
Cell Tissue Res. 2007 Apr;328(1):153-66. doi: 10.1007/s00441-006-0330-1. Epub 2006 Dec 19.
4
Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study.基质金属蛋白酶抑制剂COL-3治疗艾滋病相关卡波西肉瘤的随机II期试验：一项艾滋病恶性肿瘤协会研究
J Clin Oncol. 2006 Mar 20;24(9):1389-94. doi: 10.1200/JCO.2005.04.2614.
5
Imatinib-induced regression of AIDS-related Kaposi's sarcoma.伊马替尼诱导艾滋病相关卡波西肉瘤消退。
J Clin Oncol. 2005 Feb 10;23(5):982-9. doi: 10.1200/JCO.2005.06.079. Epub 2004 Nov 30.
6
Liquid chromatography-electrospray tandem mass spectrometric assay suitable for quantitation of halofuginone in plasma.适用于定量测定血浆中常山酮的液相色谱 - 电喷雾串联质谱分析法。
J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Oct 15;810(1):35-40. doi: 10.1016/j.jchromb.2004.07.010.
7
Smad3 as a mediator of the fibrotic response.Smad3作为纤维化反应的介质。
Int J Exp Pathol. 2004 Apr;85(2):47-64. doi: 10.1111/j.0959-9673.2004.00377.x.
8
Growth inhibition of prostate cancer xenografts by halofuginone.卤夫酮对前列腺癌异种移植瘤的生长抑制作用
Prostate. 2002 May 1;51(2):73-83. doi: 10.1002/pros.10059.
9
Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study.基质金属蛋白酶抑制剂COL-3治疗艾滋病相关卡波西肉瘤：一项I期艾滋病恶性肿瘤联盟研究。
J Clin Oncol. 2002 Jan 1;20(1):153-9. doi: 10.1200/JCO.2002.20.1.153.
10
Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor.人免疫缺陷病毒1型Tat蛋白和碱性成纤维细胞生长因子激活内皮细胞中的基质金属蛋白酶-2和膜型-1-基质金属蛋白酶并在体内诱导血管通透性
Mol Biol Cell. 2001 Oct;12(10):2934-46. doi: 10.1091/mbc.12.10.2934.
Zotero 插件